Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AGILENT TECHNOLOGIES, INC.

(A)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agilent and Visiopharm Expand Collaboration with Worldwide Distribution Agreement

09/02/2021 | 08:00am EDT

Agilent Technologies Inc. announced the signing of a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm’s portfolio of CE-IVD marked artificial intelligence (AI)-driven precision pathology software in addition to Agilent’s portfolio of automated pathology staining solutions. With an initial focus on Europe, this agreement marks Agilent's first entry into the growing digital pathology market and strengthens the relationship between the two companies by further expanding the scope of their long-term collaboration. Digital pathology is experiencing rapid growth worldwide, with its adoption expected to double by the end of this decade. As the use of digital pathology increases, AI-driven pathology solutions are emerging as the new standard. These solutions can provide diagnostic decision support and productivity enhancements that enable pathologists to improve diagnostic accuracy and workload management. This adoption has been accelerated by the COVID-19 pandemic, which has found pathologists increasingly reviewing cases remotely. In the United Kingdom, for example, pathologists have received guidance for remote reporting of digital pathology slides in times of exceptional service pressure and support in the adoption of technologies, such as digital pathology, that have the potential to aid in their assessment. Prior to this announcement, Agilent and Visiopharm have collaborated to validate Visiopharm’s existing HER2 APP to include Agilent’s new HercepTest™ mAb pharmDx for Dako Omnis, both CE-IVD marked and available for sale in Europe. Released in October 2020, this product enables pathologists to use the Visiopharm HER2 APP for objective decision support in the assessment of HercepTest™ mAb pharmDx stained slides, saving valuable time for both pathologists and patients.


© S&P Capital IQ 2021
All news about AGILENT TECHNOLOGIES, INC.
10/14VC DAILY : Sprinter Health Collects $33 Million to Join Home-Healthcare Race
DJ
10/13AGILENT TECHNOLOGIES : Eli Lilly Get FDA's OK for Assay to Identify Early Breast Cancer
MT
10/13AGILENT TECHNOLOGIES : Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 phar..
BU
10/13Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-..
CI
10/12Akadeum Life Sciences, Inc. announced that it has received $17.5 million in funding fro..
CI
10/04AGILENT TECHNOLOGIES, INC. : Ex-dividend day for
FA
09/28AGILENT TECHNOLOGIES : Announces Thought Leader Award to Bernhard Lendl at the TU Wien (Vi..
BU
09/24AGILENT TECHNOLOGIES : Dr. Mikael Dolsten Named to Agilent Board of Directors, Pfizer exec..
AQ
09/23AGILENT TECHNOLOGIES : Pfizer executive brings strong scientific and medical expertise to ..
PU
09/23AGILENT TECHNOLOGIES, INC. : Change in Directors or Principal Officers, Regulation FD Disc..
AQ
More news
Analyst Recommendations on AGILENT TECHNOLOGIES, INC.
More recommendations
Financials (USD)
Sales 2021 6 317 M - -
Net income 2021 1 075 M - -
Net Debt 2021 1 485 M - -
P/E ratio 2021 44,0x
Yield 2021 0,49%
Capitalization 46 398 M 46 398 M -
EV / Sales 2021 7,58x
EV / Sales 2022 7,06x
Nbr of Employees 16 700
Free-Float 99,7%
Chart AGILENT TECHNOLOGIES, INC.
Duration : Period :
Agilent Technologies, Inc. Technical Analysis Chart | A | US00846U1016 | MarketScreener
Technical analysis trends AGILENT TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 153,27 $
Average target price 172,40 $
Spread / Average Target 12,5%
EPS Revisions
Managers and Directors
Michael R. McMullen President, Chief Executive Officer & Director
Robert W. McMahon Chief Financial Officer & Senior Vice President
Koh Boon Hwee Non-Executive Chairman
Darlene J. S. Solomon Chief Technology Officer & Senior Vice President
Katharine Knobil Chief Medical Officer
Sector and Competitors